Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Identifieur interne : 003672 ( Main/Exploration ); précédent : 003671; suivant : 003673Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Auteurs : Valentin Goede ; Kirsten Fischer ; Raymonde Busch ; Anja Engelke ; Barbara Eichhorst ; Clemens M. Wendtner ; Tatiana Chagorova ; Javier De La Serna ; Marie-Sarah Dilhuydy ; Thomas Illmer ; Stephen Opat ; Carolyn J. Owen ; Olga Samoylova ; Karl-Anton Kreuzer ; Stephan Stilgenbauer ; Hartmut Döhner ; Anton W. Langerak ; Matthias Ritgen ; Michael Kneba ; Elina Asikanius ; Kathryn Humphrey ; Michael Wenger ; Michael HallekSource :
- The New England journal of medicine [ 1533-4406 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps monoclonaux d'origine murine (administration et posologie), Anticorps monoclonaux humanisés (administration et posologie), Anticorps monoclonaux humanisés (effets indésirables), Antigènes CD20 (immunologie), Chlorambucil (administration et posologie), Chlorambucil (effets indésirables), Comorbidité, Humains, Induction de rémission, Leucémie chronique lymphocytaire à cellules B (traitement médicamenteux), Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Rituximab, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute.
- MESH :
- administration et posologie : Anticorps monoclonaux d'origine murine, Anticorps monoclonaux humanisés, Chlorambucil.
- effets indésirables : Anticorps monoclonaux humanisés, Chlorambucil, Protocoles de polychimiothérapie antinéoplasique.
- immunologie : Antigènes CD20.
- traitement médicamenteux : Leucémie chronique lymphocytaire à cellules B.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Comorbidité, Humains, Induction de rémission, Rituximab, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (adverse effects), Antibodies, Monoclonal, Murine-Derived (administration & dosage), Antigens, CD20 (immunology), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Chlorambucil (administration & dosage), Chlorambucil (adverse effects), Comorbidity, Disease-Free Survival, Humans, Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy), Middle Aged, Remission Induction, Rituximab.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Murine-Derived, Chlorambucil.
- chemical , adverse effects : Antibodies, Monoclonal, Humanized, Chlorambucil.
- chemical , immunology : Antigens, CD20.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- drug therapy : Leukemia, Lymphocytic, Chronic, B-Cell.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Aged, 80 and over, Comorbidity, Disease-Free Survival, Humans, Middle Aged, Remission Induction, Rituximab.
Abstract
The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreated chronic lymphocytic leukemia (CLL) but not in those with coexisting conditions. We investigated the benefit of the type 2, glycoengineered antibody obinutuzumab (also known as GA101) as compared with that of rituximab, each combined with chlorambucil, in patients with previously untreated CLL and coexisting conditions.
DOI: 10.1056/NEJMoa1313984
PubMed: 24401022
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003892
- to stream PubMed, to step Curation: 003777
- to stream PubMed, to step Checkpoint: 003777
- to stream Ncbi, to step Merge: 001699
- to stream Ncbi, to step Curation: 001699
- to stream Ncbi, to step Checkpoint: 001699
- to stream Main, to step Merge: 003695
- to stream Main, to step Curation: 003672
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.</title><author><name sortKey="Goede, Valentin" sort="Goede, Valentin" uniqKey="Goede V" first="Valentin" last="Goede">Valentin Goede</name><affiliation><nlm:affiliation>From the German CLL Study Group, Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne (V.G., K.F., A.E., B.E., C.M.W., K.-A.K., M.H.), the Department for Geriatric Medicine and Research, St. Marien Hospital and University of Cologne, Cologne (V.G.), Institute of Medical Statistics and Epidemiology, Technical University Munich, Munich (R.B.), Klinikum Schwabing, Munich (C.M.W.), private oncology practice, Dresden (T.I.), Medical Department II, University of Schleswig-Holstein, City Hospital Kiel, Kiel (M.R., M.K.), the Department of Internal Medicine III, Ulm University, Ulm (S.S., H.D.), and Cluster of Excellence "Cellular Stress Responses in Aging-Associated Diseases" (CECAD), University of Cologne, Cologne (M.H.) - all in Germany; Penza Regional Oncology Dispensary, Penza (T.C.), and Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod (O.S.) - both in Russia; Servicio De Hematologia, Hospital Universitario 12 De Octubre, Madrid (J.S.); Hôpital Haut Lévêque, Bordeaux, Pessac, France (M.-S.D.); the Department of Haematology, Monash Medical Centre, Clayton, Australia (S.O.); University of Calgary, Calgary, AB, Canada (C.J.O.); the Department of Immunology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands (A.W.L.); F. Hoffmann-La Roche, Basel, Switzerland (E.A.); F. Hoffmann-La Roche, Welwyn, United Kingdom (K.H.); and Genentech, South San Francisco, CA (M.W.).</nlm:affiliation><wicri:noCountry code="subField">CA (M.W.).</wicri:noCountry></affiliation></author><author><name sortKey="Fischer, Kirsten" sort="Fischer, Kirsten" uniqKey="Fischer K" first="Kirsten" last="Fischer">Kirsten Fischer</name></author><author><name sortKey="Busch, Raymonde" sort="Busch, Raymonde" uniqKey="Busch R" first="Raymonde" last="Busch">Raymonde Busch</name></author><author><name sortKey="Engelke, Anja" sort="Engelke, Anja" uniqKey="Engelke A" first="Anja" last="Engelke">Anja Engelke</name></author><author><name sortKey="Eichhorst, Barbara" sort="Eichhorst, Barbara" uniqKey="Eichhorst B" first="Barbara" last="Eichhorst">Barbara Eichhorst</name></author><author><name sortKey="Wendtner, Clemens M" sort="Wendtner, Clemens M" uniqKey="Wendtner C" first="Clemens M" last="Wendtner">Clemens M. Wendtner</name></author><author><name sortKey="Chagorova, Tatiana" sort="Chagorova, Tatiana" uniqKey="Chagorova T" first="Tatiana" last="Chagorova">Tatiana Chagorova</name></author><author><name sortKey="De La Serna, Javier" sort="De La Serna, Javier" uniqKey="De La Serna J" first="Javier" last="De La Serna">Javier De La Serna</name></author><author><name sortKey="Dilhuydy, Marie Sarah" sort="Dilhuydy, Marie Sarah" uniqKey="Dilhuydy M" first="Marie-Sarah" last="Dilhuydy">Marie-Sarah Dilhuydy</name></author><author><name sortKey="Illmer, Thomas" sort="Illmer, Thomas" uniqKey="Illmer T" first="Thomas" last="Illmer">Thomas Illmer</name></author><author><name sortKey="Opat, Stephen" sort="Opat, Stephen" uniqKey="Opat S" first="Stephen" last="Opat">Stephen Opat</name></author><author><name sortKey="Owen, Carolyn J" sort="Owen, Carolyn J" uniqKey="Owen C" first="Carolyn J" last="Owen">Carolyn J. Owen</name></author><author><name sortKey="Samoylova, Olga" sort="Samoylova, Olga" uniqKey="Samoylova O" first="Olga" last="Samoylova">Olga Samoylova</name></author><author><name sortKey="Kreuzer, Karl Anton" sort="Kreuzer, Karl Anton" uniqKey="Kreuzer K" first="Karl-Anton" last="Kreuzer">Karl-Anton Kreuzer</name></author><author><name sortKey="Stilgenbauer, Stephan" sort="Stilgenbauer, Stephan" uniqKey="Stilgenbauer S" first="Stephan" last="Stilgenbauer">Stephan Stilgenbauer</name></author><author><name sortKey="Dohner, Hartmut" sort="Dohner, Hartmut" uniqKey="Dohner H" first="Hartmut" last="Döhner">Hartmut Döhner</name></author><author><name sortKey="Langerak, Anton W" sort="Langerak, Anton W" uniqKey="Langerak A" first="Anton W" last="Langerak">Anton W. Langerak</name></author><author><name sortKey="Ritgen, Matthias" sort="Ritgen, Matthias" uniqKey="Ritgen M" first="Matthias" last="Ritgen">Matthias Ritgen</name></author><author><name sortKey="Kneba, Michael" sort="Kneba, Michael" uniqKey="Kneba M" first="Michael" last="Kneba">Michael Kneba</name></author><author><name sortKey="Asikanius, Elina" sort="Asikanius, Elina" uniqKey="Asikanius E" first="Elina" last="Asikanius">Elina Asikanius</name></author><author><name sortKey="Humphrey, Kathryn" sort="Humphrey, Kathryn" uniqKey="Humphrey K" first="Kathryn" last="Humphrey">Kathryn Humphrey</name></author><author><name sortKey="Wenger, Michael" sort="Wenger, Michael" uniqKey="Wenger M" first="Michael" last="Wenger">Michael Wenger</name></author><author><name sortKey="Hallek, Michael" sort="Hallek, Michael" uniqKey="Hallek M" first="Michael" last="Hallek">Michael Hallek</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24401022</idno><idno type="pmid">24401022</idno><idno type="doi">10.1056/NEJMoa1313984</idno><idno type="wicri:Area/PubMed/Corpus">003892</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003892</idno><idno type="wicri:Area/PubMed/Curation">003777</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003777</idno><idno type="wicri:Area/PubMed/Checkpoint">003777</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003777</idno><idno type="wicri:Area/Ncbi/Merge">001699</idno><idno type="wicri:Area/Ncbi/Curation">001699</idno><idno type="wicri:Area/Ncbi/Checkpoint">001699</idno><idno type="wicri:Area/Main/Merge">003695</idno><idno type="wicri:Area/Main/Curation">003672</idno><idno type="wicri:Area/Main/Exploration">003672</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.</title><author><name sortKey="Goede, Valentin" sort="Goede, Valentin" uniqKey="Goede V" first="Valentin" last="Goede">Valentin Goede</name><affiliation><nlm:affiliation>From the German CLL Study Group, Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne (V.G., K.F., A.E., B.E., C.M.W., K.-A.K., M.H.), the Department for Geriatric Medicine and Research, St. Marien Hospital and University of Cologne, Cologne (V.G.), Institute of Medical Statistics and Epidemiology, Technical University Munich, Munich (R.B.), Klinikum Schwabing, Munich (C.M.W.), private oncology practice, Dresden (T.I.), Medical Department II, University of Schleswig-Holstein, City Hospital Kiel, Kiel (M.R., M.K.), the Department of Internal Medicine III, Ulm University, Ulm (S.S., H.D.), and Cluster of Excellence "Cellular Stress Responses in Aging-Associated Diseases" (CECAD), University of Cologne, Cologne (M.H.) - all in Germany; Penza Regional Oncology Dispensary, Penza (T.C.), and Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod (O.S.) - both in Russia; Servicio De Hematologia, Hospital Universitario 12 De Octubre, Madrid (J.S.); Hôpital Haut Lévêque, Bordeaux, Pessac, France (M.-S.D.); the Department of Haematology, Monash Medical Centre, Clayton, Australia (S.O.); University of Calgary, Calgary, AB, Canada (C.J.O.); the Department of Immunology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands (A.W.L.); F. Hoffmann-La Roche, Basel, Switzerland (E.A.); F. Hoffmann-La Roche, Welwyn, United Kingdom (K.H.); and Genentech, South San Francisco, CA (M.W.).</nlm:affiliation><wicri:noCountry code="subField">CA (M.W.).</wicri:noCountry></affiliation></author><author><name sortKey="Fischer, Kirsten" sort="Fischer, Kirsten" uniqKey="Fischer K" first="Kirsten" last="Fischer">Kirsten Fischer</name></author><author><name sortKey="Busch, Raymonde" sort="Busch, Raymonde" uniqKey="Busch R" first="Raymonde" last="Busch">Raymonde Busch</name></author><author><name sortKey="Engelke, Anja" sort="Engelke, Anja" uniqKey="Engelke A" first="Anja" last="Engelke">Anja Engelke</name></author><author><name sortKey="Eichhorst, Barbara" sort="Eichhorst, Barbara" uniqKey="Eichhorst B" first="Barbara" last="Eichhorst">Barbara Eichhorst</name></author><author><name sortKey="Wendtner, Clemens M" sort="Wendtner, Clemens M" uniqKey="Wendtner C" first="Clemens M" last="Wendtner">Clemens M. Wendtner</name></author><author><name sortKey="Chagorova, Tatiana" sort="Chagorova, Tatiana" uniqKey="Chagorova T" first="Tatiana" last="Chagorova">Tatiana Chagorova</name></author><author><name sortKey="De La Serna, Javier" sort="De La Serna, Javier" uniqKey="De La Serna J" first="Javier" last="De La Serna">Javier De La Serna</name></author><author><name sortKey="Dilhuydy, Marie Sarah" sort="Dilhuydy, Marie Sarah" uniqKey="Dilhuydy M" first="Marie-Sarah" last="Dilhuydy">Marie-Sarah Dilhuydy</name></author><author><name sortKey="Illmer, Thomas" sort="Illmer, Thomas" uniqKey="Illmer T" first="Thomas" last="Illmer">Thomas Illmer</name></author><author><name sortKey="Opat, Stephen" sort="Opat, Stephen" uniqKey="Opat S" first="Stephen" last="Opat">Stephen Opat</name></author><author><name sortKey="Owen, Carolyn J" sort="Owen, Carolyn J" uniqKey="Owen C" first="Carolyn J" last="Owen">Carolyn J. Owen</name></author><author><name sortKey="Samoylova, Olga" sort="Samoylova, Olga" uniqKey="Samoylova O" first="Olga" last="Samoylova">Olga Samoylova</name></author><author><name sortKey="Kreuzer, Karl Anton" sort="Kreuzer, Karl Anton" uniqKey="Kreuzer K" first="Karl-Anton" last="Kreuzer">Karl-Anton Kreuzer</name></author><author><name sortKey="Stilgenbauer, Stephan" sort="Stilgenbauer, Stephan" uniqKey="Stilgenbauer S" first="Stephan" last="Stilgenbauer">Stephan Stilgenbauer</name></author><author><name sortKey="Dohner, Hartmut" sort="Dohner, Hartmut" uniqKey="Dohner H" first="Hartmut" last="Döhner">Hartmut Döhner</name></author><author><name sortKey="Langerak, Anton W" sort="Langerak, Anton W" uniqKey="Langerak A" first="Anton W" last="Langerak">Anton W. Langerak</name></author><author><name sortKey="Ritgen, Matthias" sort="Ritgen, Matthias" uniqKey="Ritgen M" first="Matthias" last="Ritgen">Matthias Ritgen</name></author><author><name sortKey="Kneba, Michael" sort="Kneba, Michael" uniqKey="Kneba M" first="Michael" last="Kneba">Michael Kneba</name></author><author><name sortKey="Asikanius, Elina" sort="Asikanius, Elina" uniqKey="Asikanius E" first="Elina" last="Asikanius">Elina Asikanius</name></author><author><name sortKey="Humphrey, Kathryn" sort="Humphrey, Kathryn" uniqKey="Humphrey K" first="Kathryn" last="Humphrey">Kathryn Humphrey</name></author><author><name sortKey="Wenger, Michael" sort="Wenger, Michael" uniqKey="Wenger M" first="Michael" last="Wenger">Michael Wenger</name></author><author><name sortKey="Hallek, Michael" sort="Hallek, Michael" uniqKey="Hallek M" first="Michael" last="Hallek">Michael Hallek</name></author></analytic><series><title level="j">The New England journal of medicine</title><idno type="eISSN">1533-4406</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antibodies, Monoclonal, Murine-Derived (administration & dosage)</term><term>Antigens, CD20 (immunology)</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Chlorambucil (administration & dosage)</term><term>Chlorambucil (adverse effects)</term><term>Comorbidity</term><term>Disease-Free Survival</term><term>Humans</term><term>Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)</term><term>Middle Aged</term><term>Remission Induction</term><term>Rituximab</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux d'origine murine (administration et posologie)</term><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Anticorps monoclonaux humanisés (effets indésirables)</term><term>Antigènes CD20 (immunologie)</term><term>Chlorambucil (administration et posologie)</term><term>Chlorambucil (effets indésirables)</term><term>Comorbidité</term><term>Humains</term><term>Induction de rémission</term><term>Leucémie chronique lymphocytaire à cellules B (traitement médicamenteux)</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Rituximab</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antibodies, Monoclonal, Murine-Derived</term><term>Chlorambucil</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Chlorambucil</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, CD20</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux d'origine murine</term><term>Anticorps monoclonaux humanisés</term><term>Chlorambucil</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Chlorambucil</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes CD20</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Leucémie chronique lymphocytaire à cellules B</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Comorbidity</term><term>Disease-Free Survival</term><term>Humans</term><term>Middle Aged</term><term>Remission Induction</term><term>Rituximab</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Comorbidité</term><term>Humains</term><term>Induction de rémission</term><term>Rituximab</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreated chronic lymphocytic leukemia (CLL) but not in those with coexisting conditions. We investigated the benefit of the type 2, glycoengineered antibody obinutuzumab (also known as GA101) as compared with that of rituximab, each combined with chlorambucil, in patients with previously untreated CLL and coexisting conditions.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Asikanius, Elina" sort="Asikanius, Elina" uniqKey="Asikanius E" first="Elina" last="Asikanius">Elina Asikanius</name><name sortKey="Busch, Raymonde" sort="Busch, Raymonde" uniqKey="Busch R" first="Raymonde" last="Busch">Raymonde Busch</name><name sortKey="Chagorova, Tatiana" sort="Chagorova, Tatiana" uniqKey="Chagorova T" first="Tatiana" last="Chagorova">Tatiana Chagorova</name><name sortKey="De La Serna, Javier" sort="De La Serna, Javier" uniqKey="De La Serna J" first="Javier" last="De La Serna">Javier De La Serna</name><name sortKey="Dilhuydy, Marie Sarah" sort="Dilhuydy, Marie Sarah" uniqKey="Dilhuydy M" first="Marie-Sarah" last="Dilhuydy">Marie-Sarah Dilhuydy</name><name sortKey="Dohner, Hartmut" sort="Dohner, Hartmut" uniqKey="Dohner H" first="Hartmut" last="Döhner">Hartmut Döhner</name><name sortKey="Eichhorst, Barbara" sort="Eichhorst, Barbara" uniqKey="Eichhorst B" first="Barbara" last="Eichhorst">Barbara Eichhorst</name><name sortKey="Engelke, Anja" sort="Engelke, Anja" uniqKey="Engelke A" first="Anja" last="Engelke">Anja Engelke</name><name sortKey="Fischer, Kirsten" sort="Fischer, Kirsten" uniqKey="Fischer K" first="Kirsten" last="Fischer">Kirsten Fischer</name><name sortKey="Goede, Valentin" sort="Goede, Valentin" uniqKey="Goede V" first="Valentin" last="Goede">Valentin Goede</name><name sortKey="Hallek, Michael" sort="Hallek, Michael" uniqKey="Hallek M" first="Michael" last="Hallek">Michael Hallek</name><name sortKey="Humphrey, Kathryn" sort="Humphrey, Kathryn" uniqKey="Humphrey K" first="Kathryn" last="Humphrey">Kathryn Humphrey</name><name sortKey="Illmer, Thomas" sort="Illmer, Thomas" uniqKey="Illmer T" first="Thomas" last="Illmer">Thomas Illmer</name><name sortKey="Kneba, Michael" sort="Kneba, Michael" uniqKey="Kneba M" first="Michael" last="Kneba">Michael Kneba</name><name sortKey="Kreuzer, Karl Anton" sort="Kreuzer, Karl Anton" uniqKey="Kreuzer K" first="Karl-Anton" last="Kreuzer">Karl-Anton Kreuzer</name><name sortKey="Langerak, Anton W" sort="Langerak, Anton W" uniqKey="Langerak A" first="Anton W" last="Langerak">Anton W. Langerak</name><name sortKey="Opat, Stephen" sort="Opat, Stephen" uniqKey="Opat S" first="Stephen" last="Opat">Stephen Opat</name><name sortKey="Owen, Carolyn J" sort="Owen, Carolyn J" uniqKey="Owen C" first="Carolyn J" last="Owen">Carolyn J. Owen</name><name sortKey="Ritgen, Matthias" sort="Ritgen, Matthias" uniqKey="Ritgen M" first="Matthias" last="Ritgen">Matthias Ritgen</name><name sortKey="Samoylova, Olga" sort="Samoylova, Olga" uniqKey="Samoylova O" first="Olga" last="Samoylova">Olga Samoylova</name><name sortKey="Stilgenbauer, Stephan" sort="Stilgenbauer, Stephan" uniqKey="Stilgenbauer S" first="Stephan" last="Stilgenbauer">Stephan Stilgenbauer</name><name sortKey="Wendtner, Clemens M" sort="Wendtner, Clemens M" uniqKey="Wendtner C" first="Clemens M" last="Wendtner">Clemens M. Wendtner</name><name sortKey="Wenger, Michael" sort="Wenger, Michael" uniqKey="Wenger M" first="Michael" last="Wenger">Michael Wenger</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003672 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003672 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24401022
|texte= Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24401022" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |